PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: PIPELINE ANALYSIS PART 05: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Recombinant therapies - Market size and forecast 2018-2023 • Plasma-derived therapies - Market size and forecast 2018-2023 • Hormonal therapies - Market size and forecast 2018-2023 • Others - Market size and forecast 2018-2023 • Market opportunity by product PART 08: CUSTOMER LANDSCAPE PART 09: MARKET SEGMENTATION BY TYPE • On demand treatment • Prophylactic treatment • Inhibitor treatment PART 10: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • Americas - Market size and forecast 2018-2023 • EMEA - Market size and forecast 2018-2023 • APAC - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Bayer • CSL • Novo Nordisk • Pfizer • Shire PART 15: APPENDIX • Research methodology • List of abbreviations Exhibit 01: Years in consideration Exhibit 02: Global rare disease market Exhibit 03: Segments of global rare disease market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Pipeline molecules for hemophilia A Exhibit 07: Market definition - Inclusions and exclusions checklist Exhibit 08: Market size 2018 Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 10: Global market: Year-over-year growth 2019-2023 (%) Exhibit 11: Five forces analysis 2018 Exhibit 12: Five forces analysis 2023 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition - Five forces 2018 Exhibit 19: Product - Market share 2018-2023 (%) Exhibit 20: Comparison by product Exhibit 21: Recombinant therapies - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Recombinant therapies - Year-over-year growth 2019-2023 (%) Exhibit 23: Plasma-derived therapies - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Plasma-derived therapies - Year-over-year growth 2019-2023 (%) Exhibit 25: Hormonal therapies - Market size and forecast 2018-2023 ($ millions) Exhibit 26: Hormonal therapies - Year-over-year growth 2019-2023 (%) Exhibit 27: Others - Market size and forecast 2018-2023 ($ millions) Exhibit 28: Others - Year-over-year growth 2019-2023 (%) Exhibit 29: Market opportunity by product Exhibit 30: Customer landscape Exhibit 31: Market share by geography 2018-2023 (%) Exhibit 32: Geographic comparison Exhibit 33: Americas - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Americas - Year-over-year growth 2019-2023 (%) Exhibit 35: EMEA - Market size and forecast 2018-2023 ($ millions) Exhibit 36: EMEA - Year-over-year growth 2019-2023 (%) Exhibit 37: APAC - Market size and forecast 2018-2023 ($ millions) Exhibit 38: APAC - Year-over-year growth 2019-2023 (%) Exhibit 39: Key leading countries Exhibit 40: Market opportunity Exhibit 41: Decision framework Exhibit 42: Manufacturer Co-Pay Programs Exhibit 43: Impact of drivers and challenges Exhibit 44: Vendor landscape Exhibit 45: Landscape disruption Exhibit 46: Vendors covered Exhibit 47: Vendor classification Exhibit 48: Market positioning of vendors Exhibit 49: Bayer - Vendor overview Exhibit 50: Bayer - Business segments Exhibit 51: Bayer - Organizational developments Exhibit 52: Bayer - Geographic focus Exhibit 53: Bayer - Segment focus Exhibit 54: Bayer - Key offerings Exhibit 55: CSL - Vendor overview Exhibit 56: CSL - Business segments Exhibit 57: CSL - Organizational developments Exhibit 58: CSL - Geographic focus Exhibit 59: CSL - Segment focus Exhibit 60: CSL - Key offerings Exhibit 61: Novo Nordisk - Vendor overview Exhibit 62: Novo Nordisk - Business segments Exhibit 63: Novo Nordisk - Organizational developments Exhibit 64: Novo Nordisk - Geographic focus Exhibit 65: Novo Nordisk - Segment focus Exhibit 66: Novo Nordisk - Key offerings Exhibit 67: Pfizer - Vendor overview Exhibit 68: Pfizer - Business segments Exhibit 69: Pfizer - Organizational developments Exhibit 70: Pfizer - Geographic focus Exhibit 71: Pfizer - Segment focus Exhibit 72: Pfizer - Key offerings Exhibit 73: Shire - Vendor overview Exhibit 74: Shire - Business segments Exhibit 75: Shire - Organizational developments Exhibit 76: Shire - Geographic focus Exhibit 77: Shire - Key offerings Exhibit 78: Validation techniques employed for market sizing Exhibit 79: List of abbreviations

Bayer CSL Novo Nordisk Pfizer Shire